Improvement in making methods of PUVA-treated dendritic cells
Project/Area Number |
17K10135
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | Kanazawa University (2018-2019) Department of Clinical Research, National Hospital Organization Kanazawa Medical Center (2017) |
Principal Investigator |
HIDEAKI MAEBA 金沢大学, 附属病院, 特任助教 (10419335)
|
Co-Investigator(Kenkyū-buntansha) |
西村 良成 金沢大学, 附属病院, 講師 (50324116)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | GVHD / psoralen / UVA / 制御性樹状細胞 |
Outline of Final Research Achievements |
We have reported that bone marrow-derived dendritic cells (BM-DCs), which are generated from bone marrow cells plus GM-CSF, acquired tolerogenicity by PUVA-treatment(psoralen+UVA 2J/cm2) in mice.The PUVA-treated DCs have tolerogenic function in a MHC-independent manner. But these cells did not have the inhibitory effects in the mouse GVHD model. We tried to improve the manufacture condition of PUVA-DC, to make these cells engraft effectively in vivo. At first, we researched the setting (0-2 J /cm2) of the UVA radiation, but did not have acquired tolerance in the UVA 0.2-1J/cm2 setting. Next, we added caspase inhibitor to PUVA treatment for apoptotic suppression by the UVA radiation. The survival rate 24 hours after PUVA-treatment were not improved, and these cells did not have the acquired more tolerance than conventional PUVA-DC. The examination of the further culture condition is necessary to use PUVA-DC for cell therapy.
|
Academic Significance and Societal Importance of the Research Achievements |
造血幹細胞移植の合併症であるGVHDはHLA適合や免疫抑制剤の開発がなされてきた現在においてもII度以上のGVHDは非血縁者間で40%以上発症し、原疾患の治癒が得られても死亡する症例が存在する。 我々は、マウス骨髄細胞からpsolarenと紫外線(UVA)を用いて、制御性樹状細胞(PUVA-DC)を開発し、その細胞はマウスモデルでMHC非依存性にTリンパ球に対し抑制性の作用を示した。この技術を人に応用し、HLAの壁を乗り越える安全な骨髄移植開発のため、PUVA-DCの至適作製条件の検討を行った.
|
Report
(4 results)
Research Products
(12 results)
-
-
[Journal Article] Nonallergic cutaneous pigmentation is commonly observed after methotrexate administration2019
Author(s)
Yasuhiro I, Ryosei N, Raita A, Kazuhiro N, Masaki F, Toshihiro F, Rie K,Shintaro M, ,Hideaki M, Akihiro Y
-
Journal Title
J Oncol Pharm Pract
Volume: 25
Issue: 3
Pages: 769-771
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.2018
Author(s)
Ikawa Y, Nishimura R, Maeba H, Fujiki T, Kuroda R, Noguchi K, Fukuda M, Mase S, Araki R, Mitani Y, Sato T, Terui K, Ito E, Kitabayashi I, Yachie A.
-
Journal Title
Leuk Lymphoma
Volume: 印刷中
Issue: 10
Pages: 1-3
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-